The most significant development ahead of the ESMO oncology congress is a head-to-head result. Akeso's Phase III trial HARMONi-GI1 showed positive overall survival for ivonescimab plus chemotherapy against durvalumab plus chemotherapy in first-line advanced biliary tract cancer. It was selected as a Late-Breaking Abstract for the congress's Presidential Symposium.1 Durvalumab is developed by AstraZeneca, per our entity graph.2 A newer drug has therefore beaten an established big-pharma treatment in a trial. The dossier does not give the size of the survival benefit, so we do not quote one.
Summit Therapeutics announced ivonescimab data across 10 ESMO 2026 presentations. These span biliary tract, thymic carcinoma, renal cell carcinoma, endometrial, esophageal, gastric/GEJ, pancreatic, glioblastoma and head and neck cancers.3 The ESMO Congress runs October 23-27, 2026 in Madrid.18 The rest of this piece looks at what the money behind that headline looks like, and then at the wider cluster of approvals and launches around the meeting.
The company behind the headline: strong data, large losses
A positive trial and a sound business are different things. Summit's SEC filings, which we have verified, show a company spending heavily before it has anything to sell.
Summit reported zero revenue in both FY2023 and FY2024.4 It lost $614.9 million in FY2023, $221.3 million in FY2024 and $1,079.6 million in FY2025.5 Loss per share was $0.99, $0.31 and $1.44 in those three years.5 We have no revenue figure for FY2025 and do not assume one.
Cash spent by operations is smaller than the headline loss. Operating cash flow was negative $76.8 million in FY2023, negative $142.1 million in FY2024 and negative $322.9 million in FY2025.6 The dossier does not explain the gap between net loss and cash burn, so we do not guess at it. Both measures rose sharply in FY2025. Capital spending on equipment and facilities stayed small: $128,000 in FY2023, $139,000 in FY2024 and $657,000 in FY2025.7 The money goes mostly into running the programme, not into buildings.
The cash balance moved a lot over the same period:
- $28.4 million at Q2 2024, $93.8 million at Q3 2024 and $104.9 million at the end of FY2024.8
- $211.5 million at Q1 2025, $297.9 million at Q2 2025, $238.6 million at Q3 2025 and $225.3 million at the end of FY2025.8
- $106.5 million at Q1 2026, then $419.4 million at Q2 2026.8
Cash fell to $106.5 million at Q1 2026, then rose almost fourfold in one quarter. The dossier does not say where the new money came from. A jump of that size is the kind that normally comes from outside funding, but we cannot confirm that here. For a company with a $323 million annual operating cash burn, the Q2 2026 balance covers roughly 15 months at the FY2025 rate. That is our arithmetic from the verified figures, not a company forecast.
Regulators and launches
AstraZeneca announced US availability of ZEGFROVY (sunvozertinib) on October 22, 2026. It is for adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, detected by an FDA-approved test, whose disease progressed on or after platinum-based chemotherapy. The company describes it as the only approved oral, single-agent, targeted therapy for these patients following platinum-based chemotherapy.9 Mohit Manrao said: “As a leader in treating EGFR-mutated lung cancer, the US launch of ZEGFROVY marks an important step forward in our commitment to this patient community.”9 That claim of exclusivity comes from the company's own announcement.
In Europe, the CHMP, the European Medicines Agency's expert committee, adopted a positive opinion on July 24, 2026 for Gilead's Trodelvy plus Keytruda. The target is PD-(L)1-positive first-line metastatic triple-negative breast cancer. Gilead says the ASCENT-04/KEYNOTE-D19 trial showed a highly statistically significant reduction in the risk of disease progression or death.10 Evandro de Azambuja said: “This positive opinion is welcome news for our patients and the entire clinical community.”10 A CHMP opinion is a recommendation, not the final authorisation.
The topic summary also lists CHMP opinions on RASONQUE and Libtayo and an FDA decision on Tecentriq. Our dossier has no verified detail on them, so we say no more than that they are part of the same news run.
Not every data point is a drug approval. Novocure reported second-quarter 2026 revenue of $184 million, up 16% year over year, and 18% growth in active patients.11 Frank Leonard called it “our strongest quarter to date, with record net revenues and active patients on therapy.”11 A final real-world study of mogamulizumab (Poteligeo) in 109 patients from 18 German centres found a median time to next treatment of 14.9 months and a 62.4% best overall response rate.12
The “lab of the future” pitch
In the background of this news cycle is AstraZeneca's argument that AI will speed up drug discovery. The source is an MIT Technology Review piece, in which Puja Sapra describes the approach: “Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data.”13
She also names the main obstacle: “One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body.”13 On people she says: “With more autonomous systems, human oversight remains at the heart of this approach—ensuring explainable and ethical AI for the benefit of patients.”13 Her case for AstraZeneca's edge is its data: “Data is our differentiator.”13
Readers should know how reliable the source is. The article is undated in our records, and our own checks found only 6% of 16 claims extracted from it held up. That is far below the 53% measured across the news-wire sources used elsewhere in this piece. The quotes are accurate to the article, but the article describes ambitions, not results. We have seen no evidence here that any medicine has been delivered by this method.
Below the large caps, a patchier picture
The smaller companies show how uneven funding is. Spago's board resolved on October 22, 2026 to apply to delist from Nasdaq First North Growth Market. The reason given is to improve conditions for financing the next phase of Tumorad development. The move needs approval at an extraordinary general meeting.14 That meeting is planned for November 19, 2026.15 The delisting application is intended no earlier than January 25, 2027, with the last day of trading expected in February 2027.16
Akari Therapeutics took a different approach. On October 15, 2026 it said its CEO would advance AKTX-101 toward a planned Phase 1 trial in mid-2027, and it described patients whose cancer no longer responds to antibody-drug conjugates (ADCs) as a significant, growing unmet need. It says its novel payload offers an exclusive opportunity that current and most future ADCs will not be able to access.17 This is the company's own claim, not independent validation, and the trial is still about eight months away.
Do you already own any of this?
AstraZeneca is listed in the FTSE 100.2 Investors in funds that track that index may therefore hold it indirectly, though the dossier gives no weighting and we do not estimate one. Summit, Akari, Spago and the others covered here are small or specialist names, and the dossier does not place them in any index.
What to watch
- ESMO itself. Moderna and Merck planned to present detailed intismeran results on October 24 and to engage with regulators on potential filings.19 The dossier has no outcome yet.
- Summit's cash. Whether the Q2 2026 balance of $419.4 million holds up against a burn that reached $322.9 million in FY2025.68
- The size of the HARMONi-GI1 benefit. The survival result is positive, but the numbers that would show how much matter more to investors.
- Spago's November 19 vote on delisting.15
- Akari's mid-2027 start for its Phase 1 trial.17
